SAM CHUN DANG PHARM Co., Ltd.

ACTIVE

首尔特别市, South Koreawww.scd.co.krPublic408 employeesEstablished: 1978-08-28

Clinical Trials

1 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

1978

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

50.0%

Phase 2

25.0%

Phase 3

25.0%

Trial Status Distribution

Active, not recruiting

25.0%

Completed

50.0%

Recruiting

25.0%

Clinical Trials

Trials sponsored by this organization (4)

Bioavailability, Biopotency and Food Effect Study of SCD0503 Compared to Subcutaneous Regular Human Insulin

Phase 1

Recruiting

interventional

May 202616 participants

Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy

Phase 2

Completed

interventional

May 202633 participants

A clinical study to determine if a potential new drug (SCD411) is similar to the marketed product Eylea® in the efficacy, is safe and similar tolerable and distributed, by testing its effect on the body in patients with Neovascular Age-related Macular Degeneratio

Phase 1

Active, not recruiting

Jan 2021560 participants

A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)

Phase 3

Completed

interventional

Aug 2020576 participants

Approvals

No approval data available

News

No news articles found

Back to Organizations